List view / Grid view
2 February 2016 | By DiscoverX
DiscoverX Corporation announced the launch of the KILR Cytotoxicity Assay, a pioneering approach to accelerate the development of cancer immunotherapy drugs...
2 February 2016 | By Victoria White
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess ONCOS-102 in patients with malignant pleural mesothelioma...
2 February 2016 | By Victoria White
Citius is aiming for its combination cream to become the first FDA-approved prescription product to treat haemorrhoids in the US...
2 February 2016 | By Victoria White
Daiichi Sankyo has announced that it will share its clinical trial data to qualified researchers through the clinicalstudydatarequest.com system...
1 February 2016 | By Victoria White
Abbott has announced that it is to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership.
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...
1 February 2016 | By Sartorius
Sartorius grew very dynamically again in 2015 according to its preliminary figures and further increased its profitability...
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
1 February 2016 | By Victoria White
Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts...
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
29 January 2016 | By Victoria White
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam...
29 January 2016 | By Victoria White
Halaven is the first and only single agent to demonstrate an overall survival benefit in a Phase III trial in patients with leiomyosarcoma or liposarcoma...
29 January 2016 | By Victoria White
The study demonstrated superior overall survival (OS) in patients receiving Opdivo compared to the control arm...
29 January 2016 | By Victoria White
Zepatier is a once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir...
